PDT/Boston Scientific IND filing for drug/catheter combo slated for fourth quarter.
This article was originally published in The Gray Sheet
Executive Summary
PDT, INC./BOSTON SCIENTIFIC IND FILING ON DRUG/CATHETER SYSTEM FOR PROSTATE DISEASE is slated for the fourth quarter of this year, PDT says. The drug/catheter combination product, which employs photodynamic therapy to treat benign prostatic hyperplasia and prostate cancer, could enter clinicals by the end of the year following approval of the investigational new drug application, according to the company.